



The Nifty previous session ended 0.28% up at 16496.45. It opened on a positive note and remained extremely choppy throughout the session. Failing to breakout 16620 is not encouraging for the bulls, day's high was 16592.50. Breaking out critical resistance placed around 16620 looks difficult given some Index majors falling back into short-term bearish territory. Chart pattern suggests weakness is likely to persist as long as it trades below 16620 levels. Hence staying cautious on rise is advised. Downside supports are placed around 16450 and 16350 levels.

On the Nifty hourly chart, direction of the leading indicators suggests continuation of consolidation within a narrowing range. However, staying cautious on rise is advised.

Nifty patterns on multiple periods suggest; it ended the day with a Hanging Man candle, which implies indecision. Hence, staying cautious on rise is advised. Thick resistance zone is placed in the price range of 16550-16620.

Nifty Crucial Supports & Resistances-

Supports- 16450, 16350 Resistances- 16550, 16620

Open Positional Calls-

T+7 Positional Sell-
|Futures Segment| BHARTI AIRTEL
Fut @ 627-630, TGT- 600, Closing SL
- above 645

T+2 Positional Buy-
|Cash Segment| HAVELLS @ 1268-
1265, TGT- 1315, SL- closing below
1240

BTST Positional Buy-
|Cash Segment| CESC @ 731-730,
TGT- 750, SL- closing below 720

T+3 Positional Sell-
|Futures Segment| M&M Fut @ 772
-773, TGT- 747, Closing SL- above
786

Key Contents	Page No.
Result Update	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks closed higher after a volatile session, snapping a two-day losing streak, helped by technology stocks.

Nifty index ended 0.28% higher at 16,496. The broader markets represented by the NIFTY 500 Index ended 0.10% lower, ending at 13,931. Among the sectorial indices, NIFTY IT was the top gainer, gaining by 1.70%, followed by NIFTY Service gaining by 0.67%. NIFTY Media was the top loser, losing by 1.70%.

HCL Technologies was the top gainer, gaining by 4.09%, followed by Nestle India and TCS gained by 2.30% & 2.19% respectively. Grasim Industries was the top loser, losing by 2.96%, followed by Adani Ports & SE and M&M which fell by 2.75% & 2.51% respectively.

The Advance : Decline ratio stood at 689:1325

Market Turnover (In Crore) 23-08-2021

Name	Last	Previous
NSE Cash	63392.28	69324.65
NSE F&O	4534429.63	4129526.68
BSE Cash	5,746.14	5,201.19
BSE F&O	53.53	9.59

FII Derivatives Flow (In Crore) 20-08-2021*

Instrument	Purchase	Sale	Net
Index Future	5646.94	6559.47	912.53
Index Option	391105.93	382687.44	8418.49
Stock Future	23332.04	22787.73	544.31
Stock Option	32414.06	32458.54	44.48

Institutional Flow (In Crore) 20-08-2021

Institution	Purchase	Sale	Net
FII	10276.57	12563.60	2287.03
DII	6526.92	6407.62	119.30

*Data not updated till 6:15PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
HCL Technologies	4.09	3.90	9383780	4812815
Nestle India	2.30	9.59	148742	68878
TCS	2.19	5.02	3744176	3250110
Bajaj Finserv	1.96	6.67	326688	261192
Bharti Airtel	1.46	2.26	12554898	12329250

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Eicher Motors	2.22	0.11	1271399	2108963
Bajaj Auto	2.22	4.12	455643	398285
M&M	2.51	1.64	2512960	3972252
Adani Ports & SE	2.75	5.09	6636881	6133668
Grasim Industries	2.96	3.76	1163742	1224853

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	55555.79	226.47	0.41	0.21	4.87	9.92	44.55
Nifty	16496.45	45.95	0.28	0.20	4.04	8.71	45.07
BSE M Cap	22475.30	204.57	0.90	2.03	2.37	4.61	50.30
BSE S Cap	25358.02	400.09	1.55	3.78	4.04	9.63	73.39
Nifty MC 100	26892.70	232.05	0.86	2.56	2.51	5.82	58.36
BSE Auto	21899.17	278.64	1.26	3.87	3.94	5.47	22.28
BSE Capgoods	23420.45	128.01	0.54	3.69	1.78	6.09	65.27
BSE FMCG	14189.34	40.06	0.28	3.63	4.00	9.64	20.87
BSE Metal	19208.81	130.63	0.68	9.24	0.90	3.04	108.98
BSE Oil&Gas	15836.16	85.91	0.55	0.54	0.79	0.21	18.60
BSE Healthcare	25483.33	195.08	0.76	1.54	3.21	4.12	32.53
BSE Power	2676.79	8.55	0.32	1.25	0.40	5.25	53.56
BSE Realty	2955.93	25.44	0.85	6.10	7.32	15.89	67.02
BSE ConsDur	36124.79	222.53	0.61	1.28	0.35	10.53	55.81
BSE Bank	39907.30	107.42	0.27	3.02	0.19	1.58	57.87
BSE IT	33811.25	389.13	1.16	2.61	10.58	26.52	85.14

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.28	0.02	1.86	1.06	0.16	21.16	103.50
UK	0.55	0.03	5.93	3.32	5.14	33.25	168.93
Brazil	3.96	0.00	0.08	2.49	4.24	2.35	6.51
Japan	0.02	0.01	90.91	4.55	16.67	74.70	38.24
Australia	1.10	0.02	1.58	5.19	8.44	36.79	24.69
India	6.24	0.01	0.16	0.26	0.21	4.47	2.56
Switzerland	0.37	0.02	5.63	2.90	3.07	151.02	27.36
Germany	0.46	0.03	6.26	1.07	10.48	256.92	8.48

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.21	0.18	0.25	0.05	0.27	1.68	0.15
USD Index	93.31	0.19	0.20	0.73	0.43	3.66	0.07
YUAN	6.49	0.02	0.24	0.17	0.07	1.03	6.69
GBP	1.37	0.01	0.37	1.27	0.55	3.42	4.67
EUR	1.17	0.00	0.21	0.48	0.42	4.04	0.56
YEN	110.07	0.29	0.26	0.75	0.44	1.20	3.72

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	4092.00	116.00	2.92	14.75	27.91	42.63	176.30
Baltic Dirty	610.00	2.00	0.33	0.00	2.87	0.81	26.29
SG Dubai HY	0.77	0.29	60.42	7.23	6.10	23.00	87.80

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	35120.08	225.96	0.65	1.11	0.17	2.67	25.74
Nasdaq	14714.66	172.87	1.19	0.73	0.82	9.23	30.08
S&P 500	4441.67	35.87	0.81	0.59	0.68	6.88	30.75
FTSE100	7122.54	34.24	0.48	0.45	1.35	1.48	18.66
CAC40	6685.98	58.84	0.89	2.25	1.77	4.67	36.53
DAX	15849.99	40.12	0.25	0.49	1.14	2.66	24.16
Mexico IPC	51414.32	314.96	0.62	0.15	2.28	3.29	34.96
Brazil Bovespa	118052.8	888.10	0.76	2.59	5.60	3.70	16.28
Russian RTS	1645.24	21.90	1.35	1.71	3.10	4.83	30.38
Japan Nikkei	27494.24	480.99	1.78	0.11	0.20	2.91	19.96
Hang Seng	25109.59	259.87	1.05	4.09	8.10	11.77	0.02
Taiwan Index	16741.84	399.90	2.45	0.69	4.73	2.70	32.79
Shanghai Comp	3477.13	49.80	1.45	1.14	2.06	0.27	2.85
KOSPI	3090.21	29.70	0.97	2.56	5.05	2.10	34.09
Malaysia KLCI	1522.43	4.40	0.29	1.30	0.07	2.54	3.47
Jakarta Comp	6109.83	79.06	1.31	0.48	0.13	5.83	15.87
Philippine SE	6591.67	41.55	0.63	1.20	1.09	6.33	9.76
Thai Exch	1582.07	28.89	1.86	3.32	2.39	1.91	21.77

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	63.98	1.85	2.98	4.90	11.21	0.64	51.13
BRENT Crude	67.18	2.00	3.07	3.35	8.52	2.35	40.05
Natural Gas	3.90	0.05	1.35	1.09	3.44	30.40	39.54

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1789.88	8.61	0.48	0.13	0.69	4.86	7.77
Silver(\$/Ounce)	23.42	0.40	1.72	1.76	6.97	15.03	12.58
Aluminium	2562.75	0.49	0.02	1.74	4.61	8.32	46.23
Copper	9044.00	150.00	1.69	5.22	2.79	9.84	36.66
Zinc	2923.50	29.50	1.00	3.40	0.65	0.69	18.51
Lead	2447.50	20.50	0.83	0.83	4.54	10.07	24.03

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	181.70	0.20	0.11	2.44	5.34	17.42	46.00
Cotton	93.88	0.78	0.84	0.46	4.71	12.81	45.87
Sugar	19.58	0.00	0.00	2.25	7.76	16.27	55.89
Wheat	738.50	10.25	1.41	4.71	6.49	8.44	31.41
Soybean	1303.75	13.00	1.01	4.71	3.55	4.17	42.49

Euler Motors bags order for 2,500 units from e-commerce players

Electric vehicle maker Euler Motors on Monday said it has bagged a total order for 2,500 units of its upcoming electric three-wheeler cargo carrier from e-commerce players, including BigBasket and Udaan. It also includes orders from hyperlocal and business to business (B2B) delivery players for intra-city deliveries. Deliveries of these vehicles are scheduled to take place in the next 6-8 month. Currently, the company is plying over 300 vehicles as part of a pre-launch pilot with ecommerce, FMCG companies for intra-city delivery in Delhi-NCR.

Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity

Drug firm Zydus Cadila has received final approval from the US health regulator to market Tofacitinib extended-release tablets, used to treat rheumatoid arthritis, in the American market. The company said it has received approval from the US Food and Drug Administration (USFDA) for the drug in 11 mg and 22 mg strengths. Zydus was the first abbreviated new drug application (ANDA) filer on Tofacitinib extended-release tablets 22 mg and thus holds 180-day exclusivity on this strength. According to IQVIA data, Tofacitinib extended-release tablets had annual sales of around USD 2,082 million in the US for the year ending June 2021. Zydus would produce the drug at the group's formulation manufacturing facility at the SEZ. The Zydus group now has 321 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in 2003-04.

HDFC Bank aims to regain lost market share in 1 year after RBI lifts credit card ban

HDFC Bank is looking at winning back the market share by number of cards in the next one year, a senior official said on Monday. The largest private sector lender by assets was allowed to issue new credit cards by the RBI last week, over eight months after being banned from doing so due to concerns over repeated technological outages. Parag Rao, its group head for payments and consumer finance, digital banking and IT told reporters that the bank has set some milestones for itself as it seeks to re-enter the market. The first is to achieve monthly new credit card sales to 3 lakh, the number right before the ban in November 2020. Two quarters after that, it aims to take the monthly new card sales to 5 lakh a month, Rao said, adding that in three to four quarters from now, it plans to regain the market share by number of cards. During the ban, the bank lost its market share by number of cards but was able to maintain the market share on initiatives taken to prod users to spend.

Competition Commission of India fines Maruti Suzuki Rs 2 billion over dealer discount policy

Antitrust regulator has fined Maruti Suzuki, the country's biggest carmaker, 2 billion rupees (\$27 million) for anti-competitive practices related to how it forced dealers to discount cars. The Competition Commission of India (CCI) in 2019 started looking into allegations that Maruti forces its dealers to limit the discounts they offer, effectively stifling competition among them and harming consumers who could have benefited from lower prices if dealers operated freely.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Gloster Ltd	Cash dividend of INR25 effective 24-08-2021
Sundaram Finance Ltd	Cash dividend of INR6 effective 24-08-2021

Domestic Events

- No events

Global Events

- The U.S. New Home Sales for July 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com